A Review of the Rationale and Clinical Utilization of α 2 -Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders
Restricted accessReview articleFirst published online June, 2013
A Review of the Rationale and Clinical Utilization of α 2 -Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders
Interest in the potential role for the α2-adrenoceptor agonists clonidine and guanfacine as treatments for attention-deficit/hyperactivity disorder (ADHD) has driven additional clinical studies as well as development of new formulations of these agents. This article reviews the published data that supported United States Food and Drug Administration approval and subsequent clinical use of α2-adrenoceptor agonists in the treatment of ADHD, and identifies promising directions for future research.
Methods:
Electronic searches were performed in PubMed through October 2012 using the base terms ADHD or attention deficit hyperactivity disorder and alpha agonists, as well as the following limits: humans, clinical trial, meta-analysis, practice guideline, randomized controlled trial, review, English. The electronic searches were complemented with reference lists from the articles retrieved by informal search of the literature, producing a qualitative review of published, pertinent drug-class preclinical and clinical data. Articles were selected for greater exposition based on hierarchy of evidence (e.g., randomized controlled trials), relevance, and quality of individual studies, as well as generalizability to clinical practice.
Results:
Results of clinical studies of immediate-release and extended-release formulations of α2-adrenoceptor agonists and basic science investigations of cognitive effects of these drugs are discussed. Studies of both clonidine and guanfacine extended-release formulations as monotherapy and adjunctive therapy with psychostimulants for the treatment of ADHD are also reviewed.
Conclusions:
Large, randomized, placebo-controlled clinical trials support the efficacy and safety of α2-adrenoceptor agonists as monotherapy and adjunctive therapy with psychostimulants for the symptomatic treatment of ADHD. Future research could reveal whether there are cognitive benefits associated with this drug class and thus further define the role of α2-adrenoceptor agonists in the treatment of ADHD.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association. Attention-deficit and disruptive behavior disorders. Diagnostic and Statistical Manual of Mental Disorders, 4thtext revisionWashington, DC: American Psychiatric Association, 2000; 85–93.
2.
ArndtsD. New aspects of the clinical pharmacology of clonidine. Chest, 83:397–400. 1983.
3.
ArndtsD, StahleH, StruckCJ. A newly developed precise and sensitive radioimmunoassay for clonidine. Arzneimittelforschung, 29:532–538. 1979.
4.
ArnstenAF, CaiJX, Goldman–RakicPS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci, 8:4287–4298. 1988.
5.
ArnstenAF, ContantTA. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology (Berl), 108:159–169. 1992.
6.
ArnstenAF, DudleyAG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor, dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct, 1:2. 2005.
7.
ArnstenAF, ScahillL, FindlingRL. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol, 17:393–406. 2007.
8.
Aston–JonesG, CohenJD. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J Comp Neurol, 493:99–110. 2005.
9.
BarbaresiWJ, KatusicSK, ColliganRC, WeaverAL, LeibsonCL, JacobsenSJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: Results from a population-based study. J Dev Behav Pediatr, 27:1–10. 2006.
10.
BerridgeCW, WaterhouseBD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev, 42:33–84. 2003.
BiedermanJ, MelmedRD, PatelA, McBurnettK, DonahueJ, LyneA. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr, 13:1047–1055. 2008a.
13.
BiedermanJ, MelmedRD, PatelA, McBurnettK, KonowJ, LyneA, SchererN. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121:e73–e84. 2008b.
14.
BiedermanJ, NewcornJ, SprichS. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry, 148:564–577. 1991.
15.
BoellnerSW, PennickM, FiskeK, LyneA, ShojaeiA. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy, 27:1253–1262. 2007.
16.
BradyKT, GrayKM, TolliverBK. Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav, 99:285–294. 2011.
17.
BuchananML, EasterlingTR, CarrDB, ShenDD, RislerLJ, NelsonWL, MattisonDR, HebertMF. Clonidine pharmacokinetics in pregnancy. Drug Metab Dispos, 37:702–705. 2009.
18.
CarchmanSH, CroweJTJr., WrightGJ. The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. J Clin Pharmacol, 27:762–767. 1987.
Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep, 59:1439–1443. 2010.
21.
ChappellPB, RiddleMA, ScahillL, LynchKA, SchultzR, ArnstenA, LeckmanJF, CohenDJ. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry, 34:1140–1146. 1995.
22.
ChildressAC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther, 29:385–400. 2012.
23.
ConnorDF, FindlingRL, KollinsSH, SalleeF, LopezFA, LyneA, TremblayG. Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. CNS Drugs, 24:755–768. 2010.
24.
ConnorDF, FletcherKE, SwansonJM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 38:1551–1559. 1999.
25.
ConnorDF, GrassoDJ, SlivinskyMD, PearsonGS, BangaA. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents (In press)J Child Adolesc Psychopharmacol, 23:244–251. 2013.
26.
CoullJT, BuchelC, FristonKJ, FrithCD. Noradrenergically mediated plasticity in a human attentional neuronal network. Neuroimage, 10:705–715. 1999.
27.
CoullJT, NobreAC, FrithCD. The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting. Cereb Cortex, 11:73–84. 2001.
28.
CunninghamFE, BaughmanVL, PetersJ, LauritoCE. Comparative pharmacokinetics of oral versus sublingual clonidine. J Clin Anesth, 6:430–433. 1994.
DaviesDS, WingAM, ReidJL, NeillDM, TippettP, DolleryCT. Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther, 21:593–601. 1977.
31.
DavissWB, PatelNC, RobbAS, McDermottMP, BuksteinOG, PelhamWEJr., PalumboD, HarrisP, SalleeFR. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry, 47:189–198. 2008.
32.
EliaJ, AmbrosiniPJ, RapoportJL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med, 340:780–788. 1999.
33.
FaraoneSV, BuitelaarJ. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry, 19:353–364. 2010.
34.
FaraoneSV, SergeantJ, GillbergC, BiedermanJ. The worldwide prevalence of ADHD: Is it an American condition?World Psychiatry, 2:104–113. 2003.
35.
FranowiczJS, KesslerLE, BorjaCM, KobilkaBK, LimbirdLE, ArnstenAF. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci, 22:8771–8777. 2002.
HazellPL, StuartJE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry, 42:886–894. 2003.
38.
HozaB. Peer functioning in children with ADHD. Ambul Pediatr, 7:101–106. 2007.
39.
HuntRD, ArnstenAF, AsbellMD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 34:50–54. 1995.
40.
HuntRD, CapperL, O'ConnellP. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol, 1:87–102. 1990.
41.
HuntRD, MinderaaRB, CohenDJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry, 24:617–629. 1985.
42.
HuntRD, MinderaaRB, CohenDJ. The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull, 22:229–236. 1986.
JainR, KollinsS, BaileyC, HollowayW, HoracekHJ, KhayrallahM. Developing a sustained release formulation of clonidine for the treatment of children, adolescents with attention deficit hyperactivity disorder (ADHD)Poster presented at the 47th Annual Meeting of the American College of Neuropsychopharmacology, Scottsdale, AZ, December 7–11, 2008.
45.
JainR, SegalS, KollinsSH, KhayrallahM. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 50:171–179. 2011.
46.
JensenPS. Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting. Am J Manag Care, 15:S129–S140. 2009.
KarachaliosGN, CharalabopoulosA, PapalimneouV, KiortsisD, DimiccoP, KostoulaOK, CharalabopoulosK. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract, 59:562–570. 2005.
49.
KeranenA, NykanenS, TaskinenJ. Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol, 13:97–101. 1978.
50.
KiechelJR. Pharmacokinetics and metabolism of guanfacine in man: A review. Br J Clin Pharmacol, 10,Suppl 1:25S–32S. 1980.
51.
KisickiJC, FiskeK, LyneA. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther, 29:1967–1979. 2007.
52.
KollinsSH, JainR, BramsM, SegalS, FindlingRL, WigalSB, KhayrallahM. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics, 127:e1406–e1413. 2011a.
53.
KollinsSH, LopezFA, VinceBD, TurnbowJM, FarrandK, LyneA, WigalSB, RothT. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 21:111–120. 2011b.
54.
LarssonP, NordlinderA, BergendahlHT, LonnqvistPA, EksborgS, AlmenraderN, AndersonBJ. Oral bioavailability of clonidine in children. Paediatr Anaesth, 21:335–340. 2011.
55.
LevyF. Pharmacological and therapeutic directions in ADHD: Specificity in the PFC. Behav Brain Funct, 4:12. 2008.
56.
LiBM, MeiZT. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol, 62:134–139. 1994.
57.
LopezFA, WhiteC, RubinJ. Effects of guanfacine extended release on parent-reported behaviors in a randomized double-blind study of subjects with attention-deficit/hyperactivity disorder. Poster presented at the American Professional Society of ADHD and Related Disorders, Washington, DC, November 5–6, 2010.
58.
MacDonaldE, KobilkaBK, ScheininM. Gene targeting––homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci, 18:211–219. 1997.
59.
MacMillanLB, HeinL, SmithMS, PiascikMT, LimbirdLE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science, 273:801–803. 1996.
60.
ManosMJ, Tom–RevzonC, BuksteinOG, CrismonML. Changes and challenges: Managing ADHD in a fast-paced world. J Manag Care Pharm, 13:S2–S13. 2007.
61.
MullerU, ClarkL, LamML, MooreRM, MurphyCL, RichmondNK, SandhuRS, WilkinsIA, MenonDK, SahakianBJ, RobbinsTW. Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology (Berl), 182:205–213. 2005.
62.
NairV, MahadevanS. Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD. J Trop Pediatr, 55:116–121. 2009.
63.
NewcornJH, ClerkinS, SchulzKP, HalperinJM. Adrenergic agonists: Clomidine amd guanfacine. Textbook of Child and Adolescent Psychopharmacology. MartinA, ScahillL, CharneyD, LeckmanJ. New York: Oxford University Press, 2003; 264–273.
64.
NewcornJH, ClerkinS, SchulzKP, HalperinJM. Adrenergic agonists: Clonidine, guanfacine. Textbook of Child and Adolescent Psychopharmacology, 2ndMartinA., ScahillL., CharneyD., LeckmanJ.New York: Oxford University Press, 2011; 263–274.
65.
OlfsonM. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care, 10:S117–S124. 2004.
66.
PalumboDR, SalleeFR, PelhamWEJr., BuksteinOG, DavissWB, McDermottMP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry, 47:180–188. 2008.
PliszkaS. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 46:894–921. 2007.
69.
PliszkaSR, CrismonML, HughesCW, CornersCK, EmslieGJ, JensenPS, McCrackenJT, SwansonJM, LopezM. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 45:642–657. 2006.
70.
PohlGM, Van BruntDL, YeW, StoopsWW, JohnstonJA. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)BMC Health Serv Res, 9:95. 2009.
71.
PopperCW. Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol, 5:157–166. 1995.
72.
PottsAL, LarssonP, EksborgS, WarmanG, LonnqvistPA, AndersonBJ. Clonidine disposition in children; a population analysis. Paediatr Anaesth, 17:924–933. 2007.
ReiffMI, SteinMT. Attention-deficit/hyperactivity disorder evaluation and diagnosis: A practical approach in office practice. Pediatr Clin North Am, 50:1019–1048. 2003.
75.
RobbinsTW, ArnstenAF. The neuropsychopharmacology of fronto-executive function: Monoaminergic modulation. Annu Rev Neurosci, 32:267–287. 2009.
76.
RubinJ, LopezFA, YouchaS. Impact of guanfacine extended release on cognitive problems, inattention. Poster presented at the 2010 Annual Meeting of the Society for Developmental and Behavioral Pediatrics, Boston, MA, September 11–14, 2010.
77.
SalleeFR. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder. Postgrad Med, 122:78–87. 2010.
78.
SalleeFR, LyneA, WigalT, McGoughJJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 19:215–226. 2009a.
79.
SalleeFR, McGoughJ, WigalT, DonahueJ, LyneA, BiedermanJ. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 48:155–165. 2009b.
80.
SaraSJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci, 10:211–223. 2009.
81.
ScahillL, AmanMG, McDougleCJ, McCrackenJT, TierneyE, DziuraJ, ArnoldLE, PoseyD, YoungC, ShahB, GhumanJ, RitzL, VitielloB. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 16:589–598. 2006.
82.
ScahillL, BarloonL, FarkasL. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychiatr Nurs, 12:168–173. 1999.
83.
ScahillL, ChappellPB, KimYS, SchultzRT, KatsovichL, ShepherdE, ArnstenAF, CohenDJ, LeckmanJF. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry, 158:1067–1074. 2001.
84.
SchulzKP, ClerkinSM, FanJ, HalperinJM, NewcornJH. Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control. Psychopharmacology (Berl), 226:261–271. 2013.
85.
ShojaeiAH, ChangR-K, PennickM. Guanfacine extended release tablets as treatment for attention-deficit/hyperactivity disorder: Formulation characteristics. Poster presented at the U.S. Psychiatric & Mental Health Congress, New Orleans, Louisiana, November 16–19, 2006.
86.
SignorovitchJ, ErderMH, XieJ, SikiricaV, LuM, HodgkinsPS, WuEQ. Comparative effectiveness research using matching-adjusted indirect comparison: An application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf, 21:130–137. 2012.
87.
SikiricaV, HaimEM, XieJ, MacaulayD, DienerM, HodgkinsP, WuEQ. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics, 30:e1–15. 2012.
88.
SingerHS, BrownJ, QuaskeyS, RosenbergLA, MellitsED, DencklaMB. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: A double-blind placebo-controlled study with clonidine and desipramine. Pediatrics, 95:74–81. 1995.
89.
SorkinEM, HeelRC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs, 31:301–336. 1986.
90.
SpencerTJ, BiedermanJ, HardingM, O'DonnellD, FaraoneSV, WilensTE. Growth deficits in ADHD children revisited: Evidence for disorder-associated growth delays?J Am Acad Child Adolesc Psychiatry, 35:1460–1469. 1996.
91.
SpencerTJ, GreenbaumM, GinsbergLD, MurphyWR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 19:501–510. 2009.
92.
SwansonJM, FlockhartD, UdreaD, CantwellDP, ConnorP, WilliamsL. Clonidine in the treatment of ADHD: Questions about safety and efficacy. J Child Adolesc Psychopharmacol, 5:301–304. 1995.
93.
SwearingenD, PennickM, ShojaeiA, LyneA, FiskeK. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther, 29:617–625. 2007.
94.
TaylorFB, RussoJ. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol, 21:223–228. 2001.
Tourette's Syndrome Study Group:. Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 58:527–536. 2002.
97.
UhlenS, WikbergJE. Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: Computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol, 202:235–243. 1991.
98.
van der MeereJ, GunningB, StemerdinkN. The effect of methylphenidate and clonidine on response inhibition and state regulation in children with ADHD. J Child Psychol Psychiatry, 40:291–298. 1999.
99.
WangM, RamosBP, PaspalasCD, ShuY, SimenA, DuqueA, VijayraghavanS, BrennanA, DudleyA, NouE, MazerJA, McCormickDA, ArnstenAF. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell, 129:397–410. 2007.
100.
WeissYA, LaveneDL, SafarME, SimonAC, LoriaY, GeorgesDR, MilliezPL. Guanfacine kinetics in patients with hypertension. Clin Pharmacol Ther, 25:283–293. 1979.
101.
WilensTE, BuksteinO, BramsM, CutlerAJ, ChildressA, RuginoT, LyneA, GrannisK, YouchaS. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 51:74–85. 2012.
102.
WilensTE, SpencerTJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am, 9:573–603viii2000.
103.
WoodJG, CragerJL, DelapCM, HeiskellKD. Beyond methylphenidate: Nonstimulant medications for youth with ADHD. J Atten Disord, 11:341–350. 2007.
